Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Immunoassay Evaluated for Detection of Helicobacter pylori

By LabMedica International staff writers
Posted on 02 Aug 2011
The efficacy of a new polyclonal enzyme immunoassay (EIA) for the detection of Helicobacter pylori antigen in feces has been determined. More...


The immunoassay has been compared with histology, rapid urease test, carbon-13 (13C)-urea breath test, and serology to determine the optimal cut-off value for screening a population at risk.

Scientists at Seoul National University (Seoul, Korea) prospectively enrolled 515 patients undergoing a routine health check-up. H. pylori infection was defined if at least two of four of the following tests: histology, rapid urease test, 13C-urea breath test, and serology, were positive. Stool samples were analyzed using a new polyclonal EIA stool antigen test, the EZ-STEP H. pylori, which was performed by the capture of polyclonal antibodies to H. pylori absorbed in microwells. The optimal cut-off value was determined by the receiver–operator characteristic curve. The diagnostic performance of each test was evaluated with regard to the histological diagnosis of atrophic gastritis (AG)/intestinal metaplasia (IM), degree of AG/IM, and old age.

The EZ-STEP H. pylori stool antigen test (Dinona Inc., Seoul, Korea) had a sensitivity of 93.1%, and specificity of 94.6% and was accurate 93.8% of the time. The sensitivity of histology, rapid urease test, and the 13C-urea breath test ranged from 89.1% to 97.6%, and their specificity was greater than 98%. The serological test, an enzyme-linked immunosorbent assay, identified as the H. pylori IgG EIA Well (Radim diagnostics, Rome, Italy) had high sensitivity, but low specificity. The stool antigen test still showed good diagnostic performance in the setting of progression of AG/IM and in patients over 40 years.

The authors concluded that the diagnostic performance of the new polyclonal stool antigen EIA was comparable to that of other methods used in the diagnosis of H. pylori infection in the screening population if an optimal cut-off value was determined. The stool antigen test might still be effective for the detection of H. pylori in the clinical settings of AG and/or IM and elderly patients. The study was published in June 2011, in the Journal of Gastroenterology and Hepatology.

Related Links:
Seoul National University
Radim diagnostics



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.